The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 15, 2020

Filed:

Jan. 04, 2019
Applicant:

Ionis Pharmaceuticals, Inc., Carlsbad, CA (US);

Inventors:

Michael Oestergaard, Carlsbad, CA (US);

Eric E. Swayze, Encinitas, CA (US);

Punit P. Seth, Carlsbad, CA (US);

Assignee:

Ionis Pharmaceuticals, Inc., Carlsbad, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 19/00 (2006.01); C07H 21/00 (2006.01); C12N 15/113 (2010.01); C12N 15/11 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); C12N 15/111 (2013.01); C12N 2310/11 (2013.01); C12N 2310/31 (2013.01); C12N 2310/314 (2013.01); C12N 2310/315 (2013.01); C12N 2310/322 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/341 (2013.01); C12N 2310/345 (2013.01); C12N 2320/30 (2013.01); C12N 2320/34 (2013.01); C12N 2330/30 (2013.01);
Abstract

The present disclosure provides oligomeric compounds comprising at least one α-β-constrained nucleic acid as provided herein. More particularly, the α-β-constrained nucleic acid provided herein comprise an optionally modified nucleoside with a phosphorus containing constrained internucleoside linkage such as for example a cyclic phosphate internucleoside linkage. The α-β-constrained nucleic acid provided herein are expected to be useful for enhancing one or more properties of oligomeric compounds they are incorporated into such as for example nuclease resistance. In certain embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.


Find Patent Forward Citations

Loading…